Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 7.09%
As of Monday, October 05, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 7.09%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Commentary & Analysis
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 6.33%
As of Thursday, October 01, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 6.33%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 6.21%
As of Thursday, September 24, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 6.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 5.03%
As of Tuesday, September 15, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 6.07%
As of Friday, August 28, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 6.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $131.5 | $476.1 | 24% |
|
| Shares Out (Mil) | 80.9 | 42.8 | 58% |
|
| Institutional Ownership | 81.2% | 81.7% | 50% |
|
| Float (Mil) | 92.0 | 44.5 | 59% |
|
| Beta | 0.47 | 0.71 | 27% |
|
| Avg Daily Volume (000s) | 2,240 | 366 | 83% |
|
| Price Change (52-week) |
10.6% | 55.9% | 61% |
|
| Growth | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (8.8%) | (2.0%) | 30% |
|
| EPS (5yr) | 12.2% | 15.0% | 51 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (19.7%) | (15.1%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.054) | ($0.224) | ($0.230) | |
| Month Ago EPS | ($0.054) | ($0.221) | ($0.234) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.073) | ($0.254) | ($0.197) | |
| Year/Year Chg | 45.9% | (21.1%) | (83.1%) | |
| Financials | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($24) | ($11) | 22% |
|
| EPS (TTM) | ($0.236) | ($0.700) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($7) | 16% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $5 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $194 | $494 | 26% |
|
| Valuation | CRDL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.67 | 2.19 | 87% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (136.0%) | (22.2%) | 4% |
|
| ROE | (187.6%) | (21.4%) | 4% |
|
| Liabilities to Assets | 18.2% | 32.8% | 12% |
|
| F-Score | 4 | 3 | 33% |
|
Cardiol Therapeutics Inc. did not pass any screens on 10/15/2026.
